載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.3266
−US$0.002 · -0.61%
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
一般交易時段
US$0.3266
−US$0.002 · -0.61%
盤中時間採用ET。市場資料可能有所延遲。
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
日內區間
目前US$0.3266
52週區間
目前US$0.3266
盤中時間採用ET。市場資料可能有所延遲。
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
日內區間
目前US$0.3266
52週區間
目前US$0.3266
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1024.85萬 USD | 640.86萬 USD | 410.89萬 USD | 1045.12萬 USD | 138.91萬 USD |
| 銷售、一般及管理費用 | 281.41萬 USD | 243.74萬 USD | 320.12萬 USD | 66.32萬 USD | 29.62萬 USD |
| 營業費用 | 1306.27萬 USD | 884.59萬 USD | 731.01萬 USD | 1111.44萬 USD | 168.53萬 USD |
| 利息收入 | — | — | — | — | 1428 USD |
| 營業利益 | −1306.27萬 USD | −884.59萬 USD | −731.01萬 USD | −1111.44萬 USD | −168.53萬 USD |
| 淨利 | −1306.35萬 USD | −884.76萬 USD | −731.17萬 USD | −1111.44萬 USD | −168.53萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
